AU776276B2 - Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases - Google Patents

Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases Download PDF

Info

Publication number
AU776276B2
AU776276B2 AU30333/00A AU3033300A AU776276B2 AU 776276 B2 AU776276 B2 AU 776276B2 AU 30333/00 A AU30333/00 A AU 30333/00A AU 3033300 A AU3033300 A AU 3033300A AU 776276 B2 AU776276 B2 AU 776276B2
Authority
AU
Australia
Prior art keywords
disease
compound
group
disorder
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30333/00A
Other languages
English (en)
Other versions
AU3033300A (en
Inventor
Mette Gronborg
Arne Moller
Dan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU3033300A publication Critical patent/AU3033300A/en
Application granted granted Critical
Publication of AU776276B2 publication Critical patent/AU776276B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU30333/00A 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases Ceased AU776276B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900061 1999-01-19
DKPA199900061 1999-01-19
PCT/DK2000/000012 WO2000043397A1 (en) 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU3033300A AU3033300A (en) 2000-08-07
AU776276B2 true AU776276B2 (en) 2004-09-02

Family

ID=8089290

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30333/00A Ceased AU776276B2 (en) 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases

Country Status (10)

Country Link
US (1) US6576641B2 (enExample)
EP (1) EP1147113B1 (enExample)
JP (1) JP2002535334A (enExample)
CN (1) CN1147490C (enExample)
AT (1) ATE328887T1 (enExample)
AU (1) AU776276B2 (enExample)
CA (1) CA2353903A1 (enExample)
DE (1) DE60028538T2 (enExample)
NZ (1) NZ512289A (enExample)
WO (1) WO2000043397A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311386T1 (de) * 2001-09-24 2005-12-15 Bayer Pharmaceuticals Corp Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
KR102074089B1 (ko) 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
JP7187437B2 (ja) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN112135827B (zh) 2018-02-16 2024-01-12 赛诺维信制药公司 盐、晶型及其制备方法
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661498A (en) * 1984-09-27 1987-04-28 Synthelabo Furo 3,2-c pyridine derivatives and their use in treating depression and cerebral ischemia
EP0358558A1 (fr) * 1988-09-07 1990-03-14 Synthelabo Utilisation de dérivés de tétrahydro-4,5,6,7 furopyridines pour obtenir des médicaments destinés au traitement de l'obésité
US5998433A (en) * 1994-10-11 1999-12-07 Takeda Chemical Industries, Ltd. Condensed compounds, their production and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2395028A2 (fr) * 1977-06-22 1979-01-19 Centre Etd Ind Pharma Derives pyridiniques, leur preparation et leurs application therapeutique
FR2566775B1 (fr) 1984-06-27 1986-10-31 Synthelabo Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique
GB8921465D0 (en) * 1989-09-22 1989-11-08 Fujisawa Pharmaceutical Co Bicyclic amine compound and a process for the preparation thereof
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CN1250528C (zh) * 1995-09-11 2006-04-12 阿温蒂斯药物公司 环状硝酮和含有它们的药用组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661498A (en) * 1984-09-27 1987-04-28 Synthelabo Furo 3,2-c pyridine derivatives and their use in treating depression and cerebral ischemia
EP0358558A1 (fr) * 1988-09-07 1990-03-14 Synthelabo Utilisation de dérivés de tétrahydro-4,5,6,7 furopyridines pour obtenir des médicaments destinés au traitement de l'obésité
US5998433A (en) * 1994-10-11 1999-12-07 Takeda Chemical Industries, Ltd. Condensed compounds, their production and use

Also Published As

Publication number Publication date
JP2002535334A (ja) 2002-10-22
WO2000043397A1 (en) 2000-07-27
EP1147113A1 (en) 2001-10-24
DE60028538D1 (de) 2006-07-20
ATE328887T1 (de) 2006-06-15
CN1336929A (zh) 2002-02-20
US20020013336A1 (en) 2002-01-31
EP1147113B1 (en) 2006-06-07
NZ512289A (en) 2003-06-30
AU3033300A (en) 2000-08-07
US6576641B2 (en) 2003-06-10
CN1147490C (zh) 2004-04-28
DE60028538T2 (de) 2007-06-21
CA2353903A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
ES2387780T3 (es) Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas
US20190185463A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
AU776276B2 (en) Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
JP2013500975A (ja) β−アミロイド産生低減のための化合物
JP2012517971A (ja) キナーゼ阻害薬としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン類
US7045522B2 (en) 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field
JP2012514020A (ja) 置換キナゾリン化合物
US10053434B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
AU781067B2 (en) Isatine derivatives with neurotrophic activity
US10464904B2 (en) Dextrorphan-derivatives with suppressed central nervous activity
CN114591327B (zh) 吲哚啉哌啶脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用
EP1527075B1 (en) Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands
TW201446761A (zh) 蕈毒鹼（ｍｕｓｃａｒｉｎｉｃ）激動劑
WO2007060144A2 (en) Novel quinoxaline derivatives and their medical use
US20090012291A1 (en) SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA